ArticleTumori2026
Multiparametric whole-body magnetic resonance imaging in breast cancer management: A prospective study.
Article in Tumori, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiparametric Whole-Body Magnetic Resonance Imaging (WB-MRI) may enhance bone metastasis detection in metastatic breast cancer (mBC) patients. We report preliminary results from a prospective clinical trial investigating WB-MRI utility in BC patients with bone-predominant lesions, equivocal imaging findings or oligometastatic disease (OMD). Fifty-nine consecutive patients underwent baseline staging with standard imaging techniques (SIT), followed by WB-MRI. WB-MRI led to treatment-plan modifications in 40% of cases; 83% of lobular carcinoma cases exhibited additional metastases on WB-MRI. Among the 23 patients who underwent at least one reassessment by WB-MRI and SIT, the concordance rate was 69.6%. Among 18 OMD patients, WB-MRI led to the redefinition of the disease status in 44.4% of cases. These findings underscore the value of WB-MRI in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.